STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
Biotech veteran Jeremy Levin discusses the future of the biotech industry and the challenges it faces. He highlights the importance of maintaining public trust and strong institutions to support scientific advancements. Levin calls for federal changes to incentivize investment in biotech and emphasizes the need for industry leaders to speak out against regulatory issues.
- ▪Jeremy Levin is the founder and chairman of Ovid Therapeutics and former CEO of Teva Pharmaceuticals.
- ▪In his book, Levin argues that political upheaval and weakening institutions are putting the future of biotech at risk.
- ▪He advocates for federal changes to incentivize biotech investment and for companies to address regulatory challenges.
Opening excerpt (first ~120 words) tap to expand
Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk In an interview, the longtime executive explains how the field can persevere in a time of distrust Manage alerts for this article Email this article Share this article Jeremy Levin speaks at a STAT eventGreg Riccardi for STAT By Adam Feuerstein, Allison DeAngelis, and Elaine ChenMay 28, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
